Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F, Minetto P, Clavio M, Miglino M, Lemoli RM, Gobbi M. Guolo F, et al. Among authors: clavio m. Biosci Trends. 2017 Mar 22;11(1):110-114. doi: 10.5582/bst.2016.01221. Epub 2017 Jan 24. Biosci Trends. 2017. PMID: 28123146 Free article.
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.
Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, Fugazza G, Matarese S, Guardo D, Ballerini F, Di Grazia C, Raiola AM, Cagnetta A, Cea M, Miglino M, Lemoli RM, Gobbi M. Minetto P, et al. Among authors: clavio m. Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23. Br J Haematol. 2019. PMID: 29359798 Free article. No abstract available.
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.
Guolo F, Minetto P, Clavio M, Miglino M, Colombo N, Cagnetta A, Cea M, Marcolin R, Todiere A, Ballerini F, Gobbi M, Lemoli RM. Guolo F, et al. Among authors: clavio m. Br J Haematol. 2019 Sep;186(6):e223-e225. doi: 10.1111/bjh.16116. Epub 2019 Jul 26. Br J Haematol. 2019. PMID: 31348524 Free article. No abstract available.
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas.
Manconi L, Coviello E, Canale F, Giannoni L, Minetto P, Guolo F, Clavio M, Marcolin R, Cea M, Cagnetta A, Gobbi M, Miglino M, Ballerini F, Lemoli RM. Manconi L, et al. Among authors: clavio m. Leuk Lymphoma. 2020 Jan;61(1):84-90. doi: 10.1080/10428194.2019.1658102. Epub 2019 Sep 4. Leuk Lymphoma. 2020. PMID: 31480933
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, Galaverna F, Miglino M, Di Grazia C, Ballerini F, Marani C, Pastori G, Mitscheunig L, Cruciani F, Lovera D, Varaldo R, Ghiggi C, Lemoli RM, Bacigalupo A, Gobbi M. De Astis E, et al. Among authors: clavio m. Ann Hematol. 2014 Dec;93(12):2011-8. doi: 10.1007/s00277-014-2143-8. Epub 2014 Jul 4. Ann Hematol. 2014. PMID: 24989345
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, Pastori G, Guardo D, Colombo N, Kunkl A, Fugazza G, Rebesco B, Sessarego M, Lemoli RM, Bacigalupo A, Gobbi M. Guolo F, et al. Among authors: clavio m. Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15. Am J Hematol. 2016. PMID: 27084986 Free article.
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.
Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, Di Grazia C, Colombo N, Pozzi S, Ibatici A, Bagnasco S, Guardo D, Kunkl A, Ballerini F, Ghiggi C, Lemoli RM, Gobbi M, Bacigalupo A. Guolo F, et al. Among authors: clavio m. Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11. Haematologica. 2017. PMID: 28495917 Free PMC article. No abstract available.
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Cagnetta A, Soncini D, Orecchioni S, Talarico G, Minetto P, Guolo F, Retali V, Colombo N, Carminati E, Clavio M, Miglino M, Bergamaschi M, Nahimana A, Duchosal M, Todoerti K, Neri A, Passalacqua M, Bruzzone S, Nencioni A, Bertolini F, Gobbi M, Lemoli RM, Cea M. Cagnetta A, et al. Among authors: clavio m. Haematologica. 2018 Jan;103(1):80-90. doi: 10.3324/haematol.2017.176248. Epub 2017 Oct 12. Haematologica. 2018. PMID: 29025907 Free PMC article.
91 results